Taylor & Francis Group

SHERPA: Unknown

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Tallman
    Tallman
  4. Horwitz
    Horwitz
  5. Hassoun
    Hassoun
  6. Landau
    Landau
  7. Yahalom
    Yahalom
  8. Devlin
    Devlin
  9. Hay
    Hay
  10. Banerjee
    Banerjee

Groups

  1. Department of Medicine (383)
  2. Hematologic Malignancies, Division of (275)
  3. Center for Hematologic Malignancies (266)
  4. Survivorship Research (172)
  5. Population Sciences Research Program (133)
  6. Psychiatry and Behavioral Sciences, Department of (115)
  7. GSK Faculty (104)
  8. Solid Tumor Oncology Division (91)
  9. Lymphoma (89)
  10. Adult Leukemia (86)
Search Within
Formats
  1. Journal Article (774)
  2. Book Section (62)
  3. Review (59)
  4. Meeting Abstract (41)
  5. Editorial (20)
  6. Research Letter (17)
  7. Correspondence (10)
  8. Conference Paper (9)
  9. Book Whole (4)
  10. Guidelines (2)
Groups
  1. Department of Medicine (383)
  2. Hematologic Malignancies, Division of (275)
  3. Center for Hematologic Malignancies (266)
  4. Survivorship Research (172)
  5. Population Sciences Research Program (133)
  6. Psychiatry and Behavioral Sciences, Department of (115)

More Groups

People
  1. Sergio Giralt (35)
  2. Andrew Zelenetz (30)
  3. Martin Tallman (28)
  4. Philip Bialer (22)
  5. Steven Horwitz (22)
  6. Hani Hassoun (21)

More People

Years
  1. 2025 (22)
  2. 2024 (45)
  3. 2023 (39)
  4. 2022 (51)
  5. 2021 (45)
  6. 2020 (54)

More Years

Publications
  1. Leukemia and Lymphoma (307)
  2. Expert Review of Anticancer Therapy (68)
  3. Journal of Psychosocial Oncology (58)
  4. Women's Oncology Review (35)
  5. Cancer Biology and Therapy (28)
  6. Atlas of Procedures in Breast Cancer Surgery (24)

More Publications

Results (998)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes in vitrectomized versus non-vitrectomized eyes in patients with primary vitreoretinal lymphoma
    Journal Article

    Liberman, P.; Francis, J. H.; Mehrotra, K.; Tian, J.; McGarrey, M. P.; Sobol, E. K.; Thorne, J. E.; Aronow, M. E.; Berkenstock, M. K.
    Ocular Immunology and Inflammation (2023)

    Fulltext@MSK | Save
  • Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
    Journal Article

    Van Le, H.; Van Naarden Braun, K.; Nowakowski, G. S.; Sermer, D.; Radford, J.; Townsend, W.; Ghesquieres, H.; Menne, T.; Porpaczy, E.; Fox, C. P.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Chronic lymphocytic leukemia transdifferentiated to blastic neoplasm with T/plasmacytoid dendritic cell immunophenotype
    Research Letter

    Argyropoulos, K. V.; Aypar, U.; Ewalt, M. D.; Roshal, M.; Dogan, A.; Sen, F.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Personalized approaches for treatment-naìˆve mantle cell lymphoma
    Review

    Qualls, D.; Kumar, A.
    Expert Review of Hematology (2023)

    Fulltext@MSK | Save
  • A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
    Journal Article

    Palomba, M. L.; Ghione, P.; Patel, A. R.; Nahas, M.; Beygi, S.; Hatswell, A. J.; Kanters, S.; Limbrick-Oldfield, E. H.; Wade, S. W.; Ray, M. D.; more...
    Expert Review of Anticancer Therapy (2023)

    Fulltext@MSK | Save
  • Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
    Journal Article

    Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M.; Stein, E. M.; Huntington, S. F.; Zeidan, A. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: Part 3 of the open-label, multicenter, phase 1b PAVO study
    Research Letter

    Nahi, H.; Usmani, S. Z.; Mateos, M. V.; van de Donk, N. W. C. J.; Oriol, A.; Plesner, T.; Bandyopadhyay, N.; Hellemans, P.; Tromp, B.; Nnane, I.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Activating STAT5B mutations can cause both primary hypereosinophilia and lymphocyte-variant hypereosinophilia
    Research Letter

    Umrau, K.; Naganuma, K.; Gao, Q.; Dogan, A.; Kizaki, M.; Roshal, M.; Liu, Y.; Yabe, M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: Identifying risk factors to help guide treatment selection
    Journal Article

    Bantilan, K. S.; Kay, N. E.; Parikh, S. A.; Rabe, K. G.; Call, T. G.; Leis, J. F.; Ding, W.; Slager, S. L.; Soumerai, J. D.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save